Morgan Ebert, Executive Editor

Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.

Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.

Oral icotrokinra kept PASI 90 rates at ≥72% and IGA 0/1 at ≥70% from week 64 to 112 in ICONIC-LEAD, with no new safety signals.

Nichole Tyson, MD, outlines how pediatricians can evaluate menstrual concerns, identify red flags, and determine when specialty care is needed.

Maternal high egg and peanut intake in pregnancy and lactation did not lower infant IgE-mediated egg or peanut allergy at 1 year in PrEggNut.

Only 21.5% of 65 health institutions posted on Instagram in response to claims linking prenatal acetaminophen use with autism.

E-bike and e-scooter injuries nearly quadrupled from 2019 to 2025 at a pediatric hospital, with e-bike injuries associated with greater severity.

TikTok misinformation about prenatal acetaminophen and autism represented 28.3% of analyzed videos but generated more than half of total views.

Interim trial findings suggest osteopathic manipulative treatment is feasible and well-tolerated in infants with positional plagiocephaly.

New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.

A teddy bear program pairs children with stuffed animals that have matching medical devices to help normalize care and reduce device-related anxiety.

Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.

More than half of firearm-owning parents of children aged 1 to 5 years reported at least 1 firearm stored unlocked, loaded, or both.

A recap of the top clinical trial and pipeline data readouts affecting pediatric care during September 2026.

Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.

A recap of the top FDA approvals/regulatory decisions/pipeline updates affecting pediatric care during September 2026.

Mavacamten becomes the first cardiac myosin inhibitor approved for adults and pediatric patients weighing 30 kg (66 lbs) or more with symptomatic oHCM.

In a 48-patient phase 1b trial, ecnoglutide was well tolerated in adolescents with obesity and reduced BMI up to 12.6% at 20 weeks.

DBV filed a BLA for the Viaskin peanut patch in peanut-allergic children aged 4-7, citing phase 3 VITESSE data, and requested priority review.

ScolimiR-3D, a 6-microRNA blood test to predict severe curve progression in AIS, received FDA Breakthrough Device designation.

Brian Vickery, MD, discusses a phase 1 trial evaluating the safety and tolerability of a microneedle stamp designed to deliver peanut protein through the skin.

The FDA approved tiratricol (Emcitate) for peripheral thyrotoxicosis in MCT8 deficiency, the first approved therapy for the rare disorder.

FDA accepts leniolisib sNDA with priority review for children with APDS aged 4+ weighing 13 to <27 kg; PDUFA date is January 30, 2027.

FDA approves oral ALK2 inhibitor zilurgisertib for FOP in patients 12+, based on phase 2 PROGRESS data on new heterotopic ossification volume.

FDA approved obinutuzumab for relapsing or steroid-dependent childhood-onset INS, based on INShore data showing 95.5% vs 73.2% sustained remission.

Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.

In a Hirschsprung disease mouse model, diet shifted gut microbes and inflammation, with a 3-fold survival difference between standard diets.

A national claims analysis found 16.8% of pediatric GLP-1 users developed a nutritional deficiency within a year, most often vitamin D, while few received nutritional counseling.

Higher preconception maternal and paternal vitamin B12 was tied to fewer birth defects in a Shanghai cohort of 3032 couples.

Lavengratinib increased annualized height velocity in 7 children with achondroplasia, but open-label phase 2 findings remain preliminary.